Optimising a High Efficacy Plasmodium vivax Malaria Vaccine

Project Information

OptiViVax

Grant agreement ID: 101080744

DOI

10.3030/101080744

EC signature date 2 May 2023

Start date 1 June 2023

End date 31 May 2028

Funded under

• Health

Total cost

€ 3 826 044,75

EU contribution

€ 3 826 043,75

Coordinated by

STICHTING RADBOUD UNIVERSITAIR MEDISCH CENTRUM
Netherlands

CORDIS provides links to public deliverables and publications of HORIZON projects.

Links to deliverables and publications from FP7 projects, as well as links to some specific result types such as dataset and software, are dynamically retrieved from OpenAIRE .

Deliverables

Websites, patent fillings, videos etc. (2)

Press release Project start

Press release to communicate Project start, promote anticipated benefits and European Commission funding

OptiViVax website

Website with dedicated Communications materials

Publications

Peer reviewed articles (2)

Optimizing Plasmodium vivax gametocyte enrichment to enhance transmission to Anopheles mosquitoes

Author(s): Tessa Geraedts, Wakweya Chali, GJ van Gemert, Jordache Ramjith, Rianne Stoter, Kjerstin Lanke, Hester Vogelaar, Katherine Collins, Nicholas Proellochs, Angela Minassian, Simon Draper, Fitsum Tadesse, Benjamin Mordmüller, Teun Bousema, Wouter Graumans
Published in: Open Research Europe, 2026, ISSN 2732-5121
Publisher: Open Research Europe
DOI: 10.12688/OPENRESEUROPE.23635.1)

Vaccine

Author(s): Jonas E Mertens, Cassandra A Rigby, Martino Bardelli, Doris Quinkert, Mimi M Hou, Ababacar Diouf, Sarah E Silk, Chetan E Chitnis, Angela M Minassian, Robert W Moon, Carole A Long, Simon J Draper, Kazutoyo Miura
Published in: Vaccine, Issue 42, 2024, ISSN 0264-410X
Publisher: Elsevier BV
DOI: 10.1016/j.vaccine.2024.04.073.